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Objective: To determine if the use of fresh frozen plasma/frozen 
plasma 24 hours compared to solvent detergent plasma is associ-
ated with international normalized ratio reduction or ICU mortality 
in critically ill children.
Design: This is an a priori secondary analysis of a prospective, 
observational study. Study groups were defined as those trans-
fused with either fresh frozen plasma/frozen plasma 24 hours 
or solvent detergent plasma. Outcomes were international nor-
malized ratio reduction and ICU mortality. Multivariable logistic 
regression was used to determine independent associations.
Setting: One hundred one PICUs in 21 countries.
Patients: All critically ill children admitted to a participating unit 
were included if they received at least one plasma unit during 
six predefined 1-week (Monday to Friday) periods. All children 
were exclusively transfused with either fresh frozen plasma/frozen 
plasma 24 hours or solvent detergent plasma.
Interventions: None.
Measurements and Main Results: There were 443 patients 
enrolled in the study. Twenty-four patients (5%) were excluded 
because no plasma type was recorded; the remaining 419 
patients were analyzed. Fresh frozen plasma/frozen plasma 24 
hours group included 357 patients, and the solvent detergent 
plasma group included 62 patients. The median (interquar-
tile range) age and weight were 1 year (0.2–6.4) and 9.4 kg 
(4.0–21.1), respectively. There was no difference in reason 
for admission, severity of illness score, pretransfusion inter-
national normalized ratio, or lactate values; however, there 
was a difference in primary indication for plasma transfusion 
(p < 0.001). There was no difference in median (interquartile 
range) international normalized ratio reduction, between fresh 
frozen plasma/frozen plasma 24 hours and solvent detergent 
plasma study groups, –0.2 (–0.4 to 0) and –0.2 (–0.3 to 0), 
respectively (p = 0.80). ICU mortality was lower in the solvent 
detergent plasma versus fresh frozen plasma/frozen plasma 24 
hours groups, 14.5% versus 29.1%%, respectively (p = 0.02). 
Upon adjusted analysis, solvent detergent plasma transfusion 
was independently associated with reduced ICU mortality (odds 
ratio, 0.40; 95% CI, 0.16–0.99; p = 0.05).
Conclusions: Solvent detergent plasma use in critically ill children 
may be associated with improved survival. This hypothesis-gen-
erating data support a randomized controlled trial comparing sol-
vent detergent plasma to fresh frozen plasma/frozen plasma 24 
hours. (Pediatr Crit Care Med 2017; 18:e215–e223)
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Plasma products are transfused frequently. In 2013, 1,797,000 plasma units were transfused in the United States in adults and children by American Association of 
Blood Banks (AABB) member hospitals (1). According to U.S. 
pediatric health information administrative databases, nearly 
3% of all recorded pediatric admissions receive a plasma trans-
fusion during their hospital stay (2). Unfortunately, plasma 
products are also often transfused unnecessarily in both chil-
dren and adults (3, 4). This is important since there are risks 
associated with plasma use primarily in nonbleeding popula-
tions (5). Conversely, there is recent evidence indicating early 
plasma transfusion reduces death from hemorrhage in adult 
trauma patients (6). Therefore, the risk-to-benefit ratio of 
plasma transfusion is dependent upon the patient illness. How-
ever, it is also possible that the risk-to-benefit ratio of plasma 
transfusion depends upon the type of plasma transfused, since 
the characteristics of plasma vary widely according to process-
ing methods (7).
There are multiple collection/processing methods for 
plasma products. These include, but are not limited to, fresh 
frozen plasma (FFP), frozen plasma 24 hours (FP24), and 
pooled solvent/detergent-treated plasma (SDP). FFP is defined 
as plasma separated and frozen from single donor within 8 
hours of collection, and FP24 is defined as plasma collected, 
separated, and frozen within 24 hours of collection. SDP is a 
pooled plasma product developed to improve the safety profile 
of plasma. SDP is collected from over 1,000 donors who have 
been screened for nonenveloped viruses. The plasma product 
is filtered to remove cells, cell fragments, and aggregates, thus 
removing intracellular pathogens. The product is also treated 
with tri-N-butyl-phosphate for pathogen and WBC inactiva-
tion. Additionally, the product undergoes a second round of 
sterile filtration, which removes bacteria and parasites. The 
plasma product is then packed and frozen in standardized 
units. There are no large, multicenter, high-quality random-
ized controlled trials (RCTs) comparing efficacy or safety of 
FFP/FP24 to SDP products, especially in children. FFP and 
FP24 are most frequently administered in the United States, 
whereas in Europe, SDP is more commonly transfused. Pooled 
SDP has been licensed in Europe for decades and more recently 
licensed in the United States in 2013.
With the frequent use of plasma in children, it is impor-
tant to determine if different plasma processing methods can 
improve efficacy and safety. Our primary objectives for this 
hypothesis-generating study were to determine 1) if plasma 
processing relates to efficacy, by evaluating change in inter-
national normalized ratio (INR) post plasma transfusion and 
2) if plasma processing is associated with ICU mortality.
METHODS
This study is approved by the local Institutional Review Board 
at Washington University School of Medicine. This is an a priori 
planned secondary analysis of a prospective, observational study 
aimed to determine if there was an independent association 
between the type of plasma transfused and INR reduction or ICU 
mortality in critically ill children. Data were extracted from the 
recently published PlasmaTV cohort (3). One hundred one PICUs 
in 21 countries participated 
in the study. Study data were 
collected from six predefined 
1-week (Monday to Friday) 
periods. All critically ill children 
admitted to a participating ICU 
were included if they received 
at least one plasma unit during 
any of these six 1-week periods. 
Plasma transfused outside of the 
ICU was not captured in this 
study. In total, 13,192 children 
presented to site PICUs during 
the predefined weeks; of these 
children, 443 children received 
at least one plasma transfu-
sion and enrolled in the study 
(3). Twenty-four patients (5%) 
were excluded from our analy-
sis because no plasma type was 
recorded; the remaining 419 
patients were analyzed. The Plas-
maTV study collected laboratory 
data that were ordered clinically. 
It did not require pre and post 
plasma transfusion laboratory 
analyses to be performed.
Figure 1. Receiver operating characteristic (ROC) curve of the final multivariable model. The area under the 
curve was 0.85 (95% CI, 0.80–0.89). Model: Reason for PICU admission, day 1 Pediatric Logistic Organ 
Dysfunction-2 score, highest log lactate on day of transfusion, plasma type transfused, continuous renal 
replacement therapy during transfusion, log total volume of plasma per kilogram.
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Clinical indications for plasma transfusion were categorized 
as follows: 1) Critical bleeding: massive bleeding (transfusion 
of all blood products > 80 mL/kg within 24 hr), bleeding in spe-
cific sites (intracranial, intraocular, retroperitoneal, intraspi-
nal, pericardial, and nontraumatic intra-articular), or bleeding 
requiring a surgical intervention or drainage (e.g., hemothorax 
requiring drainage). 2) Minor bleeding: minor surgical bleeding 
(wound, drain, etc.) or minor nonsurgical bleeding (endotra-
cheal tube secretions, nasogastric tube, urine, etc.). 3) Planned 
surgery or procedures: central venous catheter, pleural drain, 
etc. 4) High risk of postoperative bleeding: as defined by the 
intensivist. 5) No bleeding, no planned procedure: hypovole-
mia, abnormal coagulation tests, factor or component replace-
ment, at high risk of bleeding due to nonsurgical reasons.
Descriptive statistics were used to report continuous and 
dichotomous variables. Continuous variables are reported as 
median and interquartile range (IQR). Dichotomous variables 
are reported as n (%). Unadjusted comparisons of continu-
ous and categorical variables used Wilcoxon rank sum test and 
Fisher exact test, respectively. To assess which variables were 
potential confounders for ICU mortality, variables were com-
pared for patients who survived or did not survive in the ICU.
To establish independent associations between variables 
recorded and mortality, a multivariable logistic regression model 
was developed. The adjusted model was determined by forward 
and backward stepwise selection of baseline characteristics 
associated with mortality. Candidate variables must have had a 
p value of less than or equal to 0.20 on unadjusted analyses, which 
TablE 1. Relationship between Type of Plasma and Population Characteristics
Candidate Independent Variables
Fresh Frozen Plasma/ 
Frozen Plasma 24 hr  
(n = 357)
Pooled Solvent/Deter-
gent-Treated Plasma 
(n = 62) p
Gender, n (%)   0.78
 Male 152 (42.6) 25 (40.3)  
 Female 205 (57.4) 37 (59.7)  
Age, yr, median (IQR) 1.1 (0.2–6.4) 0.8 (0.3–6.3) 0.80
Reason for admission, n (%)   0.88
 Medical only 142 (39.8) 23 (37.1)  
 Surgical only 133 (37.3) 25 (40.3)  
 Combination of medical and surgical 82 (23.0) 14 (22.6)  
Primary indication for plasma transfusion, n (%)   < 0.001
 No bleeding, no procedure 128 (35.9) 17 (27.4)  
 Critical bleeding 81 (22.7) 10 (16.1)  
 Minor bleeding 64 (17.9) 27 (43.6)  
 Preparation/planned procedure 44 (12.3) 6 (10.0)  
 High risk of postoperative bleeding 40 (11.2) 2 (3.2)  
Pediatric Logistic Organ Dysfunction -2 score at transfusion, median 
(IQR)
7 (5–10) 7 (5–9)
0.26
INR prior to transfusion, median (IQR)a 1.6 (1.3–2.0) 1.5 (1.2–1.9) 0.89
Change in INR, posttransfusion minus pretransfusion, median (IQR)b –0.2 (–0.4 to 0) –0.2 (–0.3 to 0) 0.80
Highest lactate on day of transfusion, median (IQR)c 2.6 (1.5–5.0) 2.3 (1.6–4.3) 0.72
Extracorporeal life support during transfusion, n (%) 36 (10.1) 4 (6.5) 0.49
Continuous renal replacement therapy during transfusion, n (%) 28 (7.8) 6 (9.7) 0.62
Intermittent hemodialysis 4 (1.1) 1 (1.6) 0.55
Total volume of plasma (mL/kg), median (IQR)d 21.4 (11.1–55.4) 15.0 (10.0–40.9) 0.07
Mortality, n (%) 104 (29.1) 9 (14.5) 0.02
INR = international normalized ratio, IQR = interquartile range.
a Comparison limited to 309 patients with day 1 international normalized ratio (INR) measured.
b Comparison limited to 270 patients with pre and posttransfusion INR measured.
c Comparison limited to 368 patients with lactate on day of transfusion measured.
d Comparison limited to 415 patients with total volume of plasma recorded.
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included patient age, reason for PICU admission, indication for 
plasma transfusion, day 1 Pediatric Logistic Organ Dysfunction 
(PELOD)-2 score, extracorporeal life support (ECLS) and con-
tinuous renal replacement therapy (CRRT) during transfusion, 
lactate level, and total volume per kilogram of plasma during 
PICU stay. Lactate concentrations and total volume per kilo-
gram of plasma transfused had nonnormal distributions and 
were hence log-transformed for use in regression analyses. INR 
prior to transfusion was not included in the multivariable model 
as this measure was not available for approximately 26% of the 
study population. These variables were then assessed with for-
ward and backward stepwise models, with study group forced 
into the models. Inclusion threshold for the stepwise processes 
was set to p value of less than 0.05. Candidate variables that met 
the stepwise process threshold of p value less than 0.05 in either 
stepwise model developed were included the final model. Area 
under the receiver operator characteristic (ROC) curve for the 
adjusted model was calculated to assess the model’s predictive 
ability (Fig. 1). The Hosmer-Lemeshow goodness-of-fit test was 
also performed to assess whether or not the observed event rates 
match expected event rates in subgroups of the model popu-
lation. Multicollinearity between variables was assessed and 
determined not to be of issue in this analysis. For comparison, 
unadjusted logistic regression models were generated for each 
candidate variable. All analyses were conducted using SAS 9.4 
(SAS Institute, Cary, NC).
TablE 2. Relationship between ICU Mortality and Population Characteristics
Candidate Independent Variables
Not Deceased  
(n = 306)
Deceased  
(n = 113) p
Gender, n (%)   0.66
 Male 127 (41.5) 50 (44.3)  
 Female 179 (58.5) 63 (55.8)  
Age, yr, median (IQR) 1.3 (0.3–6.5) 0.8 (0.1–5.4) 0.16
Reason for admission, n (%)   < 0.001
 Medical only 106 (34.6) 59 (52.2)  
 Surgical only 134 (43.8) 24 (21.2)  
 Combination of medical and surgical 66 (21.6) 30 (26.6)  
Primary indication for plasma transfusion, n (%)   0.02
 No bleeding, no procedure 100 (32.7) 45 (39.8)  
 Critical bleeding 59 (19.3) 32 (28.3)  
 Minor bleeding 77 (25.2) 14 (12.4)  
 Preparation/planned procedure 36 (11.8) 14 (12.4)  
 High risk of postoperative bleeding 34 (11.1) 8 (7.1)  
Pediatric Logistic Organ Dysfunction-2 score at transfusion, median (IQR) 7 (5–9) 11 (8–15) < 0.001
INR prior to transfusion, median (IQR)a 1.5 (1.3–1.9) 1.7 (1.4–2.8) 0.003
Change in INR, posttransfusion minus pretransfusion, median (IQR)b –0.2 (–0.4 to 0.0) –0.2 (–0.6 to 0) 0.90
Highest lactate on day of transfusion, median (IQR)c 2.1 (1.4–3.9) 4.3 (1.9–9.1) < 0.001
Plasma type, n (%)   0.02
 Fresh frozen plasma/frozen plasma 24 hr 253 (82.7) 104 (92.0)  
 Solvent/detergent-treated plasma 53 (17.3) 9 (8.0)  
Extracorporeal life support during transfusion, n (%) 20 (6.5) 20 (17.7) 0.001
Continuous renal replacement therapy during transfusion, n (%) 14 (4.6) 20 (17.7) < 0.001
Intermittent hemodialysis 4 (1.3) 1 (0.9) 1.00
Total volume of plasma (mL/kg), median (IQR)d 17.3 (10.2–41.2) 35.9 (16.4–105.4) < 0.001
INR = international normalized ratio, IQR = interquartile range.
a Comparison limited to 309 patients with day 1 international normalized ratio (INR) measured.
b Comparison limited to 270 patients with pre and posttransfusion INR measured.
c Comparison limited to 368 patients with lactate on day of transfusion measured.
d Comparison limited to 415 patients with total volume of plasma recorded.
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RESUlTS
There were 443 critically ill children enrolled in the study. Twenty-
four patients (5%) were excluded because no plasma type was 
recorded, and one patient (0.2%) was transfused with Mirasol-
treated plasma (TerumoBCT, Lakewood, CO); the remaining 419 
patients were analyzed. Forty-two percent (177/419) of the patient 
population were males. The median (IQR) age and weight were 1.0 
year (0.2–6.4) and 9.4 kg (4.0–21.1), respectively. Mortality rate in 
all patients was 27% (113/419). Thirty-nine percent (165/419) of 
patients were admitted for medical reasons only, 38% (158/419) 
were admitted for surgical reasons only, and 23% (96/419) were 
admitted for a combination of medical and surgical reasons. All 
children received either FFP/FP24 (n = 357) or SDP (n = 62) exclu-
sively. No patients received a mixture of FFP/FP24 and SDP.
When comparing the two study groups, there was no dif-
ference in gender, age, or reason for admission. There was a 
significant difference between the two groups for the primary 
indication for plasma transfusion (p ≤ 0.001). The FFP/FP24 
group had a higher proportion of patients were transfused for 
critical bleeding, no bleeding, or planned procedure, compared 
to the SDP group. The SDP group had a higher proportion of 
patients transfused for minor bleeding compared to the FFP/
FP24 group (Table 1). More patients were transfused SDP for 
any type of bleeding (critical and minor) than were trans-
fused FFP/FP24, 59.7% versus 40.6%, respectively (p = 0.009). 
There was no difference in illness severity parameters between 
the two groups such as PELOD-2 scores, pretransfusion INR, 
or highest lactate on day of transfusion (Table 1). The differ-
ence in total volume of plasma transfused in the FFP/FP24 
group compared to the SDP group approached significance 
(p = 0.07). Although there was no difference in INR reduction 
between both study groups, there was reduced mortality in the 
SDP group compared to the FFP/FP24 group, 14.5% (9/62) 
versus 29.1% (104/357), respectively (p = 0.02) (Table 1).
Variables associated with ICU mortality were reason 
for admission, primary indication for plasma transfusion, 
PELOD-2 score at transfusion, INR prior to transfusion, high-
est lactate on day of transfusion, type of plasma type trans-
fused, total volume of plasma (mL/kg) transfused, ECLS use, 
and CRRT use (Table 2).
When comparing the two study groups, we also analyzed 
ICU mortality for each transfusion indication (Table 3). 
For each plasma transfusion indication evaluated, the ICU 
mortality rate was lower in the SDP group, though these 
values did not reach statistical significance. There was no 
one plasma indication that was significant for a reduction 
in ICU mortality with SDP, although there was a numerical 
reduction in ICU mortality in each group when SDP was 
transfused.
Table 4 indicates the variables associated with ICU mortal-
ity by univariate regression analysis. In this unadjusted model, 
use of SDP was associated with reduced ICU mortality (odds 
ratio [OR], 0.41; 95% CI, 0.20–0.87; p = 0.02).
Multivariable logistic regression showed a two-fold decrease 
in mortality after adjustment for confounding variables that 
were marginally significant (OR, 0.40; 95% CI, 0.16–0.99; 
p = 0.05) (Table 5). As expected, severity of illness as measured 
by the PELOD-2 score or need for CRRT were both indepen-
dently associated with increased ICU mortality. The volume 
per kilogram of either plasma product was also independently 
associated with increased ICU mortality. Due to nonsignifi-
cance during the stepwise process, upon adjusted analysis, 
plasma transfusion indication was removed from the model. 
The Hosmer-Lemeshow goodness-of-fit test (p = 0.40) dem-
onstrates that the data fit the logistic distribution. The adjusted 
model shows good predictive ability, with an area under the 
ROC equals to 0.85.
DISCUSSION
This prospective, observational study is the first analysis examining 
the association between plasma processing methods and outcomes 
in critically ill children. Our analysis indicates that although no 
difference in INR reduction was observed, upon adjustment, SDP 
transfusion was independently associated with a two-fold reduc-
tion in ICU mortality when compared with FFP/FP24 products.
The literature regarding the effect of plasma on outcomes in 
pediatric patients is scant. One pediatric study examining FFP 
and FP24 use reported a 41% prevalence of new or progressive 
multiple organ dysfunction syndrome in patients transfused 
TablE 3.  ICU Mortality Per Indication of 
Plasma Transfusion by Study Group
Indication
ICU Mortality, 
n (%) p
No bleeding, no procedure  0.58
 FFP/FP24 (n = 128) 41 (32.0)  
 SDP (n = 17) 4 (23.5)  
Critical bleeding  0.48
 FFP/FP24 (n = 81) 30 (37.0)  
 SDP (n = 10) 2 (20.0)  
Minor bleeding  0.22
 FFP/FP24 (n = 64) 12 (18.8)  
 SDP (n = 27) 2 (7.4)  
Preparation/planned procedure  0.66
 FFP/FP24 (n = 44) 13 (30.0)  
 SDP (n = 6) 1 (16.7)  
High risk of postoperative bleeding  1.00
 FFP/FP24 (n = 40) 8 (20.0)  
 SDP (n = 2) 0 (0.0)  
All indications  0.02
 FFP/FP24 (n = 357) 104 (29.1)  
 SDP (n = 62) 9 (14.5)  
FFP/FP24 = fresh frozen plasma/frozen plasma 24 hr, SDP = solvent/
detergent-treated plasma.
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with FFP/FP24 compared to an 8% incidence for those not 
transfused at all (p < 0.001). There was a 17% incidence of nos-
ocomial infections in the FFP/FP24 group compared to 3.7% 
incidence in patients not transfused (p = 0.04). There was no 
significant difference in 28-day mortality; however, there was a 
significant difference in the length of ICU stay (8).
In adults, plasma transfusion with FFP/FP24 in predominantly 
nonbleeding or nonmassive bleeding cohorts has independently 
been associated with increased morbidity (5) and mortality in 
trauma patients (9, 10), patients with gastrointestinal bleeding 
(11), and critically ill patients (12). FFP/FP24 transfusion has 
also been associated with increased incidence of acute respiratory 
distress syndrome (13), transfusion-related acute lung injury 
(TRALI) (14), transfusion-associated circulatory overload (15), 
nosocomial infections (16), and multiple organ failure in non-
massively bleeding patients (17). Conversely, in a secondary anal-
ysis of a large RCT, increased plasma use relative to RBCs with 
FFP/FP24 in massively bleeding adult trauma patients reduces 
death from hemorrhage and the time to hemostasis (6, 18).
Although similar types of analyses have not been per-
formed with SDP, European data in general indicate that it has 
an increased safety profile compared to FFP/FP24 products. 
In one observational study, patients who were transfused a 
pooled SDP product had an 83% reduction in adverse reac-
tions and no cases of TRALI compared to those receiving 
FFP (19). Another analysis evaluating the risk associated 
with FFP and Octaplas (Octapharma, Lachen, Switzerland), 
a SDP product, showed that in countries where Octaplas is 
transfused, there were no reported cases of TRALI compared 
to 22 cases reported where FFP is transfused (20). A recent 
small RCT compared SDP and FFP in orthotopic liver trans-
plant patients in whom thromboelastography was used to 
direct the indication for plasma transfusion. In this study, 
there was a statistically significant reduction in the amount 
of plasma needed to correct coagulopathy in patients receiv-
ing Octaplas compared to those receiving FFP (21). Other 
data indicate that in adult patients undergoing open-heart 
surgery, SDP is equally as effective at correcting coagulopa-
thy when compared with FFP (18).
Our results indicate no difference in efficacy between study 
groups for INR reduction. Possible reasons for this could be 
that INR reduction itself may not be the most accurate measure 
reflecting coagulation or there could simply be no difference 
in efficacy between the groups. Future studies comparing SDP 
TablE 4. Unadjusted logistic Regression Models of Independent Variables and ICU 
Mortality
Candidate Independent Variables OR (95% CI) p
Reason for admission  0.0002
 Surgical only Reference  
 Medical only 3.11 (1.81–5.33) < 0.0001
 Combination of medical and surgical 2.54 (1.38–4.68) 0.003
Primary indication for plasma transfusion  0.02
 No bleeding, no procedure Reference  
 Critical bleeding 1.21 (0.69–2.10) 0.51
 Minor bleeding 0.40 (0.21–0.79) 0.008
 Preparation/planned procedure 0.86 (0.43–1.76) 0.69
 High risk of postoperative bleeding 0.52 (0.22–1.22) 0.13
Pediatric Logistic Organ Dysfunction-2 score at transfusion 1.31 (1.22–1.40) < 0.0001
International normalized ratio prior to transfusiona 1.39 (1.15–1.68) 0.0006
Highest log lactate on day of transfusionb 2.27 (1.71–3.01) < 0.0001
Plasma type   
 Fresh frozen plasma/frozen plasma 24 hr Reference  
 Solvent/detergent-treated plasma 0.41 (0.20–0.87) 0.02
Extracorporeal life support during transfusion, yes vs no 3.08 (1.59–5.97) 0.0009
Continuous renal replacement therapy during transfusion, yes vs no 4.49 (2.18–9.23) < 0.0001
Log total volume of plasma (mL/kg)c 1.52 (1.27–1.82) < 0.0001
OR = odds ratio.
a Comparison limited to 309 patients with day 1 international normalized ratio measured.
b Comparison limited to 368 patients with lactate on day of transfusion measured.
c Comparison limited to 415 patients with total volume of plasma recorded.
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and FFP/FP24 products should incorporate other measures 
that reflect thrombin formation such as viscoelastic measures 
and thrombin generation assays, in addition to reducing clini-
cally significant bleeding and associated clinical outcomes, to 
further evaluate plasma efficacy. Thrombin generation poten-
tial between samples from FFP and SDP units has been dem-
onstrated to be different in “in vitro” experiments, especially 
when FFP remained thawed for up to 5 days (7). In this report, 
total thrombin generation of thawed plasma is reduced at day 
5 compared to day 0, and there were more platelet and RBC 
microparticles in FFP compared to SDP. Since our analysis and 
previously published studies that evaluated the association 
between FFP/FP24 and outcomes have not reported the stor-
age duration of “thawed plasma,” it is not possible to assess if 
this has contributed to the results reported. It is important for 
future studies to record the storage duration of thawed plasma 
since a recent AABB survey indicates that approximately 
30–53% of all plasma transfused is thawed and then stored 
between 1 and 5 days before transfusion in the United States 
(1, 22). One hypothesis is that the reduced thrombin genera-
tion and increased platelet and RBC-derived microparticles 
affect the efficacy and safety of FFP/FP24 products, especially 
when thawed and stored, compared to SDP (7). This hypoth-
esis requires analysis in prospective human studies.
Although there was no difference in INR reduction, our 
results suggest there may be an association with reduced ICU 
mortality with SDP compared to the FFP/FP24 group. The 
reduction in ICU mortality, according to the type of plasma 
transfused, was diffusely distributed among the indications 
for plasma transfusion, suggesting that the association was 
not limited to a specific indication (Table 3). The lack of sta-
tistical significance in this subgroup analysis may be due to 
the reduced power with a smaller sample size in each sub-
group. The potential reduction in ICU mortality could again 
be due to the improved safety profile of SDP, specifically the 
pooling process, which dilutes anti-human leukocyte anti-
gen and anti-human neutrophil antigen antibodies, and the 
extraction phase and filtering, which removes microparticles 
and biologically reactive mediators. The potential mecha-
nisms are speculative and require investigation. In order to 
further evaluate the potential effects on efficacy and safety of 
SDP versus FFP/FP24, RCTs are needed that include mecha-
nistic ancillary studies. We have estimated the sample size 
needed to assess the relationship between plasma type and 
mortality in a prospective study. Based on an OR of 0.4 and 
ICU mortality of 0.29 (95% CI, 0.24–0.35), we estimate a 
sample size of 226 to 310 participants would be required.
The independent association of increased volume per kilo-
gram of either FFP/FP24 or SDP transfused with poor out-
comes in our analysis is consistent with previous reports with 
FFP in pediatric patients (8). It is unknown if there is a dose-
effect of plasma on worse outcomes in certain clinical scenar-
ios or if these findings represent confounding by indication.
Limitations of this prospective study include its lack of ran-
domization and risk of selection bias. The differences in the 
indication for plasma between study groups could be a source of 
bias, but plasma indication was removed from the model for ICU 
mortality due to nonsignificance, and critical bleeding, which was 
more common as an indication for transfusion in the FFP/FP2 
group, was not associated with ICU mortality on univariate analy-
sis (Table 4). The inability to adjust for RBC or platelet volumes 
transfused, as well as for center effect, is also limitations. The lack 
of cause of death for patients in the analysis also reduced our abil-
ity to interpret our results. The noninclusion of plasma transfused 
outside the ICU, for example, during cardiopulmonary bypass, 
is another limitation. The low number of patients who received 
SDP may have also reduced the power of our analysis as well as 
its generalizability. In addition, we cannot exclude that patients 
received a different type of plasma before the study period started; 
therefore, although the plasma types were exclusive to one group 
TablE 5. Multiple logistic Regression Model of Independent Variables and ICU Mortality
Candidate Independent Variables OR (95% CI) p
Reason for admission  0.01
 Surgical only Reference  
 Medical only 2.76 (1.39–5.46) 0.004
 Combination of medical and surgical 2.09 (0.94–4.65) 0.07
Day 1 Pediatric Logistic Organ Dysfunction-2 score 1.24 (1.14–1.35) < 0.0001
Highest log lactate on day of transfusion 1.45 (1.00–2.10) 0.05
Plasma type  0.05
 Fresh frozen plasma/frozen plasma 24 hr Reference  
 Solvent/detergent-treated plasma 0.40 (0.16–0.99) 0.05
Continuous renal replacement therapy during transfusion, yes vs no 2.50 (1.08–5.79) 0.03
Log total volume of plasma (mL/kg) 1.59 (1.26–2.00) < 0.0001
OR = odds ratio.
Variables placed in the model that were not reported due to nonsignificance include indication for plasma transfusion, patient age, and use of extracorporeal life 
support.
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or another during the study, we cannot confirm it was prior to 
the initiation of data collection for the PlasmaTV study. However, 
this was an a priori planned prospective study, from 21 countries 
and with large patient cohort with a strong multivariable logistic 
regression model that is hypothesis generating in nature.
CONClUSIONS
In this large, international, prospective cohort study of criti-
cally ill children, SDP had a similar effect on INR reduction 
when compared with FFP/FP24 products and was marginally 
significant for a reduction in ICU mortality. Our results sup-
port the development of prospective trials to further analyze 
the efficacy and safety of SDP transfusions compared to FFP or 
FP24 in critically ill children.
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